Indications
Sofosbuvir goes straight for the Hepatitis C virus and stops it making copies of itself in the liver. It does this by attaching to the virus's genetic information, called RNA, which blocks the virus from multiplying. Daclatasvir works alongside it as a direct-acting antiviral agent (DAA) against the Hepatitis C virus.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Sofosbuvir blocks the hepatitis C virus (HCV) enzyme NS5B RNA-dependent RNA polymerase, which the virus needs to replicate. It is a nucleotide prodrug, so it is changed inside the cell into its active form, a uridine analog triphosphate called GS-461203. The NS5B polymerase takes GS-461203 into the HCV RNA, and there it acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a, with a 50% inhibitory concentration (IC50) value ranging from 0.7 to 2.6 micrometer. GS-461203, the active metabolite of sofosbuvir, does not inhibit human DNA or RNA polymerases, and it does not inhibit mitochondrial RNA polymerase either.
Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting the HCV protein NS5A. NS5A is critical for HCV viral transcription and translation.